Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes of retesting BRCA negative patients using multigene panels.

Familial cancer - 1 Jul 2017

Yadav Siddhartha, Reeves Ashley, Campian Sarah, Paine Amy, Zakalik Dana

Abstract excerpt

The utility of multigene panels in retesting patients who previously tested negative for a pathogenic mutation by BRCA1/2 testing is not well established. Patients who previously tested negative for a pathogenic BRCA1/2 mutation by standard sequencing, and who were seen in cancer genetics center between November 1, 2012 and June 30, 2015 for additional testing utilizing multigene panels, were identified using our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Genetic Testing

Share to Registries

Source

Identifiers

PMID: 27878467
DOI: 10.1007/s10689-016-9956-7

Genes

BRCA1
BARD1
APC
ATM
CDH1
CHEK2
PALB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes of retesting BRCA negative patients using multigene panels.PMID 27878467Read ↗

Multigene panel testing results in patients with multiple breast cancer primaries.Semantic proximity Read ↗

Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.Semantic proximity Read ↗

Initial Results of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome.Semantic proximity Read ↗

Detection rates of multigene panel and exome testing in patients with previous negative BRCA1/2 results.Semantic proximity Read ↗

Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working GroupSemantic proximity Read ↗

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.Semantic proximity Read ↗

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Semantic proximity Read ↗

Multigene panel testing reveals the spectrum of non-BRCA germline variants in BRCA1/2-negative breast, ovarian, and prostate cancer patients from a Turkish cohort.Semantic proximity Read ↗

Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2Semantic proximity Read ↗

Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.Semantic proximity Read ↗

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.Semantic proximity Read ↗

The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.